Fintel reports that on June 7, 2024, Wells Fargo initiated coverage of J.B. Hunt Transport Services (NasdaqGS:JBHT) with a Overweight recommendation.
Fintel reports that on June 7, 2024, Morgan Stanley initiated coverage of AerCap Holdings N.V. (NYSE:AER) with a Equal-Weight recommendation.
Fintel reports that on June 7, 2024, Wells Fargo initiated coverage of C.H. Robinson Worldwide (NasdaqGS:CHRW) with a Equal-Weight recommendation.
Fintel reports that on June 7, 2024, Raymond James initiated coverage of Third Harmonic Bio (NasdaqGM:THRD) with a Outperform recommendation.
Zacks Investment Research has recently initiated coverage of Atrion Corporation ATRI with a Neutral recommendation. The research report on Atrion, a Texas-based developer and manufacturer of medical devices, provides an in-depth a
Zacks Investment Research has recently initiated coverage of Weyco Group, Inc. WEYS with a Neutral recommendation. The comprehensive report highlights the company's strategic positioning within the global footwear industry alongsi
Zacks Investment Research has recently initiated coverage of Cato Corporation CATO with a Neutral recommendation. The report highlights both the strengths and challenges facing the fashion retailer, providing investors with a bala
Fintel reports that on June 6, 2024, Janney Montgomery Scott initiated coverage of Annaly Capital Management (NYSE:NLY) with a Buy recommendation.
Fintel reports that on June 5, 2024, BMO Capital initiated coverage of Old Dominion Freight Line (NasdaqGS:ODFL) with a Outperform recommendation.
Fintel reports that on June 5, 2024, Goldman Sachs initiated coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Neutral recommendation.
Fintel reports that on June 4, 2024, B. Riley Securities initiated coverage of Carlyle Credit Income Fund (NYSE:CCIF) with a Buy recommendation.
Fintel reports that on May 31, 2024, Piper Sandler initiated coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) with a Neutral recommendation.
Fintel reports that on May 31, 2024, Piper Sandler initiated coverage of Allogene Therapeutics (NasdaqGS:ALLO) with a Overweight recommendation.